Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"},{"orgOrder":0,"company":"Halix BV","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Halix BV"},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc\u2019s Sabin-IPV Vaccine Eupolio Receives WHO Prequalification to Treat Poliomyelitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Intravacc"},{"orgOrder":0,"company":"Intravacc","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc\u2019s Inactivated Polio Vaccine, Out Licensed to Sinovac, Receives Market Authorization in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Intravacc"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"SIFI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sifi Announces License Agreement with Avanzanite Bioscience for Akantior\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Avanzanite Bioscience"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Avanzanite Bioscience

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sifi Announces License Agreement with Avanzanite Bioscience for Akantior®

              Details:

              AKANTIOR® (polihexanide) is an investigational anti-amoebic polymer that has been granted Orphan Drug Designation by both the European Medicines Agency ("EMA") and Food and Drug Administration ("FDA") for AK.

              Lead Product(s): Polyhexanide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: SIFI

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Intravacc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Intravacc’s Inactivated Polio Vaccine, Out Licensed to Sinovac, Receives Market Authorization in China

              Details:

              The approval of Sinovac’s polio vaccine (sIPV) by the NMPA in China is a major milestone in the ongoing efforts towards global polio eradication & to reduce the vaccine-associated paralytic polio caused by oral polio vaccines, which are based on live attenuated polio viruses.

              Lead Product(s): sIPV

              Therapeutic Area: Infections and Infectious Diseases Product Name: sIPV

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Sinovac Biotech

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AM-Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

              Details:

              The REVIVAL trial is a Phase III pivotal study evaluating AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with SA-AKI.

              Lead Product(s): Recombinant Human Alkaline Phosphatase

              Therapeutic Area: Infections and Infectious Diseases Product Name: Ilofotase Alfa

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Intravacc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Intravacc’s Sabin-IPV Vaccine Eupolio Receives WHO Prequalification to Treat Poliomyelitis

              Details:

              Eupolio was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative. Eupolio™ received the prequalification status from the WHO by the end of December.

              Lead Product(s): Sabin-inactivated polio vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Eupolio

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Halix BV

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine

              Details:

              Under the agreement, HALIX will provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX expands with two additional viral vector production lines.

              Lead Product(s): ChAdOx1 nCoV-19

              Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration December 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Douglas Pharma, a New Zealand success story, with CDMO capabilities for softgels, liquids, tablets, capsules & powders.
              Post Enquiry
              POST ENQUIRY